Yalçin Burçe, Kalkanci Ayşe, Gürelik Feryal, Fidan Işil, Kustimur Semra, Ozdek Sengül
Gazi Universitesi Tip Fakültesi, Tibbi Mikrobiyoloji Anabilim Dali, Ankara.
Mikrobiyol Bul. 2010 Jan;44(1):65-70.
Contradictory results such as synergy or indifferent effect, have been reported about the interactions between quinolones and antifungal drugs in different studies. The aim of this study was to investigate the in vitro susceptibilities of Candida spp. to moxifloxacin (MOX) alone and MOX + amphotericin B (AmB) combination. A total of 20 strains were included to the study, of which 19 were clinical isolates (10 Candida albicans, 4 Candida glabrata, 2 Candida parapsilosis, 1 Candida tropicalis, 1 Candida pelliculosa ve 1 Candida sake) and 1 was a standard strain (C. albicans ATCC 90028). In vitro susceptibilities of the strains to MOX with AmB were investigated by broth microdilution method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI), and in vitro interaction of these drugs were determined by a chequerboard titration method. Minimal inhibitory concentration (MIC) values of Candida spp. for MOX were found > or = 400 microg/ml indicating that MOX, by itself has no antifungal activity. AmB MIC values were found 1 microg/ml in 11 of the clinical isolates, and < or = 0.5 microg/ml in the other 8 clinical isolates and 1 standard strain. The inhibitor activity of AmB was slightly enhanced when combined with MOX, there being a decrease of 1-4 fold dilutions in the AmB MICs against all isolates tested. Synergistic effect between MOX and AmB, defined as a fractional inhibitory concentration (FIC) index as < or = 0.5, was observed in 90% (18/20; all were clinical isolates) of the strains, whereas indifferent effect (FIC = 1) was detected in 10% (2/20; 1 was clinical and 1 was standard strain) of the strains. Antagonistic effect was not observed for this combination even at 48th hours. It was concluded that these preliminary results should be confirmed by large-scaled in vitro and in vivo studies to evaluate MOX + AmB combination as a therapeutic option for the treatment of Candida infections.
在不同研究中,关于喹诺酮类药物与抗真菌药物之间的相互作用报告了相互矛盾的结果,如协同作用或无差异作用。本研究的目的是调查念珠菌属对莫西沙星(MOX)单独使用以及MOX与两性霉素B(AmB)联合使用时的体外敏感性。共有20株菌株纳入研究,其中19株为临床分离株(10株白色念珠菌、4株光滑念珠菌、2株近平滑念珠菌、1株热带念珠菌、1株膜状念珠菌和1株清酒念珠菌),1株为标准菌株(白色念珠菌ATCC 90028)。根据临床和实验室标准协会(CLSI)的建议,采用肉汤微量稀释法研究菌株对MOX与AmB联合使用时的体外敏感性,并通过棋盘滴定法确定这些药物的体外相互作用。念珠菌属对MOX的最低抑菌浓度(MIC)值≥400μg/ml,表明MOX本身无抗真菌活性。在11株临床分离株中,AmB的MIC值为1μg/ml,在其他8株临床分离株和1株标准菌株中,AmB的MIC值≤0.5μg/ml。当与MOX联合使用时,AmB的抑菌活性略有增强,针对所有测试分离株,AmB的MIC值稀释倍数降低了1 - 4倍。在90%(18/20;均为临床分离株)的菌株中观察到MOX与AmB之间的协同作用,定义为分数抑菌浓度(FIC)指数≤0.5,而在10%(2/20;1株为临床分离株,1株为标准菌株)的菌株中检测到无差异作用(FIC = 1)。即使在48小时时,该联合用药也未观察到拮抗作用。得出的结论是,这些初步结果应通过大规模的体外和体内研究加以证实,以评估MOX + AmB联合用药作为治疗念珠菌感染的一种治疗选择。